Jun 14, 2024 · As we noted in last year’s report, Novo Nordisk and Eli Lilly, competing in the lucrative GLP-1 receptor agonist space that, of late, has captivated the US and beyond in weight loss, are knocking loudly on the top-10 door.Both companies, who own the highest market caps, respectively, in pharma, turned in massive growth in our latest Pharma 50.

Master the Science of Success through aspirational coverage for executive-level decisions, leadership, management, strategy and commercialization professionals.

Jun 10, 2023 · Movers and shakers. As mentioned, Pfizer and AbbVie captured the top two spots again in the Pharma 50—the latter, notably, expected to maintain its solid momentum, even with Humira’s patent expiration this year, thanks to reinforcements Skyrizi for psoriasis (up 75.7% in sales in 2022 to $5.2 billion) and JAK inhibitor Rinvoq (with seven approvals so far, including rheumatoid arthritis and ...

Dec 25, 2024 · In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.

Developments in the world of artificial intelligence continue to accelerate at a rapid pace. Our November issue of Pharmaceutical Executive explores a few of those that are starting to deliver measurable gains for the industry.

Master the Science of Success through aspirational coverage for executive-level decisions, leadership, management, strategy and commercialization professionals.

Company: Elevar Therapeutics Agency: The Agency Network at MJH LifeSciences Campaign: Elevar uHCC Disease Awareness Campaign

Jan 29, 2025 · Joseph Panetta, President and CEO of Biocom California, shares his insights on biotech industry trends, policy challenges, and educational initiatives, drawing from over 25 years of leadership in California’s thriving life sciences sector.

Oct 3, 2024 · Master the Science of Success through aspirational coverage for executive-level decisions, leadership, management, strategy and commercialization professionals.

In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the …